株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:メチシリン耐性黄色ブドウ球菌 (MRSA) の疫学的予測 2024年

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 345360
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
EpiCast Report:メチシリン耐性黄色ブドウ球菌 (MRSA) の疫学的予測 2024年 EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024
出版日: 2015年10月13日 ページ情報: 英文 62 Pages
概要

2014年において、主要7市場 (米国、フランス、ドイツ、イタリア、スペイン、英国および日本) におけるメチシリン耐性黄色ブドウ球菌 (MRSA) の感染による入院事例は79万7,883件となりました。この数字は2024年までに88万4,727件へ増加すると予測されています。入院事例は米国、フランス、イタリア、スペイン、英国および日本で増加していますが、ドイツでは減少しています。

当レポートでは、世界の主要7市場におけるメチシリン耐性黄色ブドウ球菌 (MRSA) の診断症例数および入院患者数の推移について調査し、今後10年間の予測を提供しており、疾患の背景、リスク要因と併存症、年齢・性別・感染場所別の診断症例数・予測などについてまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク要因と併存症
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
    • 使用ソース
    • 未使用ソース
    • 予測の前提条件・手法
  • メチシリン耐性黄色ブドウ球菌 (MRSA) 疫学的予測
    • MRSAの入院事例
    • MRSAの入院事例:性別
    • MRSAの入院事例:年齢別
    • MRSAの入院事例:年齢調整比率
    • MRSAの入院事例の割合:感染場所別
    • MRSAの入院事例の割合:症例定義
  • 検証
    • 疫学的予測の考察
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考資料
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

目次
Product Code: GDHCER097-15

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections (SSTIs). The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Scope

  • The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
  • The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MRSA EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global MRSA market.
  • Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
  • Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for MRSA (2014-2024)
    • 3.5.1. Hospitalized Incident Cases of MRSA
    • 3.5.2. Sex-Specific Hospitalized Incident Cases of MRSA
    • 3.5.3. Age-Specific Hospitalized Incidence of MRSA
    • 3.5.4. Age-Standardized Hospitalized Incidence Rate of MRSA
    • 3.5.5. Proportion of Hospitalized Incident MRSA Cases by Infection Site
    • 3.5.6. Proportion of Hospitalized Incident MRSA Cases by Case Definition
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for MRSA
  • Table 2: Definitions of HA-MRSA and CA-MRSA
  • Table 3: US, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 4: France, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 5: Germany, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 6: Italy, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 7: Spain, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 8: UK, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 9: Japan, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 10: 7MM, Hospitalized Incident Cases of MRSA, Men and Women, All Ages, N, 2014-2024
  • Table 11: 7MM, Sex-Specific Hospitalized Incident Cases of MRSA, All Ages, N, 2014
  • Table 12: 7MM, Age-Specific Hospitalized Incident Cases of MRSA, Men and Women, N, 2014

List of Figures

  • Figure 1: US, Methodology for Calculation of MRSA Hospitalized Incident Cases
  • Figure 2: 5EU, Methodology Used to Calculate the MRSA Hospitalized Incident Cases by Infection Type
  • Figure 3: 7MM, Hospitalized Incident Cases of MRSA, Men and Women, All Ages, N, 2014-2024
  • Figure 4: 7MM, Sex-Specific Hospitalized Incident Cases of MRSA, All Ages, N, 2014
  • Figure 5: 7MM, Age-Specific Hospitalized Incident Cases of MRSA, Men and Women, N, 2014
  • Figure 6: 7MM, Age-Standardized Hospitalized Incidence Rate of MRSA, 2014
  • Figure 7: 7MM, Proportion of Hospitalized Incident MRSA Cases by Infection Site, Men and Women, All Ages
  • Figure 8: 7MM, Proportion of Hospitalized Incident MRSA Cases by Case Definition, Men and Women, All Ages
Back to Top